Skip to main content
Premium Trial:

Request an Annual Quote

Hybrigen, Bionomics Expand Target-Discovery Collaboration

NEW YORK, Jan. 30 - Hybrigen and Bionomics have expanded their drug target-discovery relationship to include a new angiogenesis target discovered by Bionomics, the companies said on Wednesday.

 

They also announced plans jointly to launch a new enterprise to commercialize discoveries made in the collaboration.

 

The two companies inked a target discovery partnership last September to study two genes linked to breast cancer. Bionomics had identified and patented the genetic data, and Hybrigen brought its proteomic expertise to discover relevant drug targets. The two companies share rights to any drug targets developed in that collaboration.

 

The relationship will now include Bionomics' angiogenesis genes to which it has rights. Again, both companies will co-own the drug targets.

 

Bionomics, based in Adelaide, Australia, focuses on discovering and characterizing disease-related genes, especially in breast cancer, epilepsy, and angiogenesis.

 

Hybrigen is headquartered in Dallas, Tex. It has developed a proteomic platform to assist in drug target-discovery and characterization.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.